<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02532686</url>
  </required_header>
  <id_info>
    <org_study_id>NSC-101-2314-B-039-030-MY3</org_study_id>
    <nct_id>NCT02532686</nct_id>
  </id_info>
  <brief_title>DAAOI-2 add-on Treatment for Treatment-resistant Schizophrenia</brief_title>
  <official_title>DAAOI-2 add-on Treatment for Treatment-resistant Schizophrenia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>China Medical University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ministry of Science and Technology, Taiwan</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>China Medical University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Pharmacotherapy for schizophrenia has limitations such as residual positive and negative&#xD;
      symptoms, cognitive deficits and intolerable side effects. Refractory schizophrenia is still&#xD;
      a difficult clinical issue at present. According to the N-methyl-D-aspartate (NMDA)&#xD;
      hypothesis, adjuvant NMDA-enhancing agents may have therapeutic benefit. DAAOI-2, a D-amino&#xD;
      acid oxidase (DAAO) inhibitor, is a NMDA-enhancing agent. The aim of this project is to&#xD;
      examine the effectiveness and safety of DAAOI-2 add-on treatment for treatment-resistant&#xD;
      schizophrenia patients in a randomized, double-blind, placebo-controlled trial.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Pharmacotherapy for schizophrenia has limitations such as residual positive and negative&#xD;
      symptoms, cognitive deficits and intolerable side effects. Refractory schizophrenia is still&#xD;
      a difficult clinical issue at present. According to the N-methyl-D-aspartate (NMDA)&#xD;
      hypothesis, many clinical trials on NMDA-enhancing agents were studied. Adjuvant&#xD;
      NMDA-enhancing agents, including glycine, D-amino acids such as D-serine, and sarcosine (a&#xD;
      glycine transporter I inhibitor), revealed beneficial but limited efficacy for positive and&#xD;
      negative symptoms.&#xD;
&#xD;
      The aim of this project is to examine the effectiveness and safety of DAAOI-2 add-on&#xD;
      treatment for treatment resistant schizophrenia patients in a randomized, double-blind,&#xD;
      placebo - controlled trial.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2014</start_date>
  <completion_date type="Actual">July 2016</completion_date>
  <primary_completion_date type="Actual">July 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Positive and Negative Syndrome Scale(PANSS)</measure>
    <time_frame>baseline</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Positive and Negative Syndrome Scale(PANSS)</measure>
    <time_frame>2 weeks after the trial</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Positive and Negative Syndrome Scale(PANSS)</measure>
    <time_frame>4 weeks after the trial</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Positive and Negative Syndrome Scale(PANSS)</measure>
    <time_frame>6 weeks after the trial (The end of the trial)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Assessment of Negative symptoms(SANS)</measure>
    <time_frame>baseline</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Assessment of Negative symptoms(SANS)</measure>
    <time_frame>2 weeks after the trial</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Assessment of Negative symptoms(SANS)</measure>
    <time_frame>4 weeks after the trial</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Assessment of Negative symptoms(SANS)</measure>
    <time_frame>6 weeks after the trial (The end of the trial)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>PANSS subscales</measure>
    <time_frame>baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PANSS subscales</measure>
    <time_frame>2 weeks after the trial</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PANSS subscales</measure>
    <time_frame>4 weeks after the trial</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PANSS subscales</measure>
    <time_frame>6 weeks after the trial (The end of the trial)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Global Impression (CGI)</measure>
    <time_frame>baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Global Impression (CGI)</measure>
    <time_frame>2 weeks after the trial</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Global Impression (CGI)</measure>
    <time_frame>4 weeks after the trial</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Global Impression (CGI)</measure>
    <time_frame>6 weeks after the trial (The end of the trial)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Global assessment of function (GAF)</measure>
    <time_frame>baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Global assessment of function (GAF)</measure>
    <time_frame>2 weeks after the trial</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Global assessment of function (GAF)</measure>
    <time_frame>4 weeks after the trial</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Global assessment of function (GAF)</measure>
    <time_frame>6 weeks after the trial (The end of the trial)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hamilton Depression Rating Scale (HAMD)</measure>
    <time_frame>baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hamilton Depression Rating Scale (HAMD)</measure>
    <time_frame>2 weeks after the trial</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hamilton Depression Rating Scale (HAMD)</measure>
    <time_frame>4 weeks after the trial</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hamilton Depression Rating Scale (HAMD)</measure>
    <time_frame>6 weeks after the trial (The end of the trial)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life scale (QOL)</measure>
    <time_frame>baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life scale (QOL)</measure>
    <time_frame>2 weeks after the trial</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life scale (QOL)</measure>
    <time_frame>4 weeks after the trial</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life scale (QOL)</measure>
    <time_frame>6 weeks after the trial (The end of the trial)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>&quot;Measurement and Treatment Research to Improve Cognition in Schizophrenia [MATRICS]</measure>
    <time_frame>baseline</time_frame>
    <description>An intergrated score from 7 domains:&#xD;
speed of processing: category fluency, trail making A, and digit symbol - coding from Wechsler adult intelligence scale (WAIS-III);&#xD;
sustained attention: continuous performance test;&#xD;
verbal and nonverbal working memory: backward digit span and spatial span from Wechsler memory scale (WMS-III);&#xD;
verbal learning and memory: word listing from WMS-III;&#xD;
visual learning and memory: visual reproduction from WMS-III;&#xD;
reasoning and problem solving: maze from Wechsler intelligence scale for children (WISC-III);&#xD;
social cognition: the managing emotions branch of Mayer-Salovey-Caruso emotional intelligence test (MSCEIT)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>&quot;Measurement and Treatment Research to Improve Cognition in Schizophrenia [MATRICS]</measure>
    <time_frame>6 weeks after the trial (The end of the trial)</time_frame>
    <description>An intergrated score from 7 domains:&#xD;
speed of processing: category fluency, trail making A, and digit symbol - coding from Wechsler adult intelligence scale (WAIS-III);&#xD;
sustained attention: continuous performance test;&#xD;
verbal and nonverbal working memory: backward digit span and spatial span from Wechsler memory scale (WMS-III);&#xD;
verbal learning and memory: word listing from WMS-III;&#xD;
visual learning and memory: visual reproduction from WMS-III;&#xD;
reasoning and problem solving: maze from Wechsler intelligence scale for children (WISC-III);&#xD;
social cognition: the managing emotions branch of Mayer-Salovey-Caruso emotional intelligence test (MSCEIT)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Schizophrenia</condition>
  <arm_group>
    <arm_group_label>DAAOI-2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>DAAOI-2: 500-2000mg/d</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DAAOI-2</intervention_name>
    <description>500-2000mg/d, oral, for 6 weeks</description>
    <arm_group_label>DAAOI-2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>oral, for 6 weeks</description>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Fulfill the DSM-IV criteria of schizophrenia&#xD;
&#xD;
          -  Treatment resistant: No satisfactory response to at least two kinds of antipsychotics&#xD;
&#xD;
          -  Remain symptomatic but without clinically significant fluctuation and the&#xD;
             antipsychotic doses are unchanged for at least 3 months&#xD;
&#xD;
          -  Have a minimum baseline total score of 70 on the Positive and Negative Syndrome Scale&#xD;
             (PANSS)&#xD;
&#xD;
          -  Agree to participate in the study and provide informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Meet DSM-IV criteria of substance (including alcohol) abuse or dependence&#xD;
&#xD;
          -  Meet DSM-IV criteria of mental retardation&#xD;
&#xD;
          -  Serious medical or neurological illness&#xD;
&#xD;
          -  Pregnancy or lactation&#xD;
&#xD;
          -  Inability to follow protocol&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Department of Psychiatry, China Medical University Hospital</name>
      <address>
        <city>Taichung</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <study_first_submitted>August 10, 2015</study_first_submitted>
  <study_first_submitted_qc>August 23, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 26, 2015</study_first_posted>
  <last_update_submitted>January 29, 2018</last_update_submitted>
  <last_update_submitted_qc>January 29, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 30, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>China Medical University Hospital</investigator_affiliation>
    <investigator_full_name>Hsien-Yuan Lane</investigator_full_name>
    <investigator_title>Department of Psychiatry</investigator_title>
  </responsible_party>
  <keyword>Treatment resistant</keyword>
  <keyword>DAAOI</keyword>
  <keyword>NMDA</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Schizophrenia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

